"uuid:ID","name","instanceType","id","description","rationale","label"
"eb7785b9-6e98-4193-b6c6-22f6ae71c3eb","Study Design 1","StudyDesign","StudyDesign_1","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.",""
